A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Authors: Hagman, H, Author, Frodin, J-E, Author, Berglund, A, Author, Sundberg, J, Author, Vestermark, LW, Author, Albertsson, M, Author, Fernebro, E, Author, Johnsson, A, Author

Contributors: Hagman, H, Author, Frodin, J-E, Author, Berglund, A, Author, Sundberg, J, Author, Vestermark, LW, Author, Albertsson, M, Author, Fernebro, E, Author, Johnsson, A, Author

Source: ANNALS OF ONCOLOGY. 27(1):140-147

Access URL: https://ki.se/en/research/search-research-information?t=2&query=id%3A509907

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Authors: Sorbye, H, Author, Welin, S, Author, Langer, SW, Author, Vestermark, LW, Author, Holt, N, Author, Osterlund, P, Author, Dueland, S, Author, Hofsli, E, Author, Guren, MG, Author, Ohrling, K, Author

Contributors: Sorbye, H, Author, Welin, S, Author, Langer, SW, Author, Vestermark, LW, Author, Holt, N, Author, Osterlund, P, Author, Dueland, S, Author, Hofsli, E, Author, Guren, MG, Author, Ohrling, K, Author

Source: ANNALS OF ONCOLOGY. 24(1):152-160

Access URL: https://ki.se/en/research/search-research-information?t=2&query=id%3A534687

Triple Chemotherapy (DOX) in Patients with Advanced Gastro-Esophageal Adenocarcinoma - A Phase II Study

Authors: Tarpgaard, LS, primary, Jensen, M, additional, Schønnemann, KR, additional, Jensen, HA, additional, Vestermark, LW, additional, Yilmaz, M, additional, Pfeiffer, P, additional

Source: International Journal of Cancer and Clinical Research. 2021/03/19

Access URL: https://www.clinmedjournals.org/articles/ijccr/international-journal-of-cancer-and-clinical-research-ijccr-8-147.pdf?jid=ijccr

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)

Authors: Vestermark LW (AUTHOR), Jacobsen A (AUTHOR), Qvortrup C (AUTHOR), Hansen F (AUTHOR), Bisgaard C (AUTHOR), Baatrup G (AUTHOR), Rasmussen P (AUTHOR), Pfeiffer P (AUTHOR)

Source: Acta Oncologica. Apr2008, Vol. 47 Issue 3, p428-433. 6p.

URL: 31314076

Genetic intratumour heterogeneity in digestive high-grade neuroendocrine neoplasms.

Authors: Morken S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Sorbye H; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Deng W; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Dogramaci HT; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Venizelos A; Department of Clinical Science, University of Bergen, Bergen, Norway., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Hofsli E; Department of Oncology, St. Olavs Hospital, Trondheim, Norway., Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway., Couvelard A; Pathology Department, Bichat Hospital AP-HP and Université Paris Cité, Paris, France., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Knappskog S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.

Source: Journal of neuroendocrinology [J Neuroendocrinol] 2026 Oct; Vol. 38 (10), pp. e70296.

Publication Type: Journal Article

Journal Info: Publisher: Wiley & Sons Country of Publication: United States NLM ID: 8913461 Publication Model: Print Cited Medium: Internet ISSN: 1365-2826 (Electronic) Linking ISSN: 09538194 NLM ISO Abbreviation: J Neuroendocrinol Subsets: MEDLINE

MeSH Terms: Neuroendocrine Tumors*/genetics , Neuroendocrine Tumors*/pathology , Digestive System Neoplasms*/genetics , Digestive System Neoplasms*/pathology , Genetic Heterogeneity*, Humans ; Mutation ; Female ; Male ; Neoplasm Grading

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

Authors: Morken S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Sundlöv A; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden., Hofsli E; Department of Oncology, St. Olav's Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg University, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Tabaksblat E; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Knigge U; Department of Surgery, ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Endocrinology, ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Nunes L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Glimelius B; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Aasebø K; Cancer Clinic, Haukeland University Hospital, Bergen, Norway., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Vassella E; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Couvelard A; Department of Pathology, Bichat Hospital AP-HP and Paris Cité University, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Knappskog S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Sorbye H; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.

Source: International journal of cancer [Int J Cancer] 2026 Jun 15; Vol. 158 (12), pp. 3217-3231. Date of Electronic Publication: 2026 Feb 05.

Publication Type: Journal Article; Comparative Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

MeSH Terms: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/mortality , Adenocarcinoma*/drug therapy , Adenocarcinoma*/genetics , Adenocarcinoma*/pathology , Adenocarcinoma*/mortality , Carcinoma, Neuroendocrine*/drug therapy , Carcinoma, Neuroendocrine*/genetics , Carcinoma, Neuroendocrine*/pathology , Carcinoma, Neuroendocrine*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Aged ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Adult ; Mutation ; Aged, 80 and over

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Authors: Sorbye H; Cancer Clinic, Haukeland University Hospital, Bergen, Norway. halfdan.sorbye@helse-bergen.no.; Department of Clinical Science, University of Bergen, Bergen, Norway. halfdan.sorbye@helse-bergen.no., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Sundlöv A; Department of Oncology, Skåne University Hospital, Lund, Sweden., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Hofsli E; Department of Oncology, St.Olavs Hospital, Trondheim, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Morken S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Tabaksblat E; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Couvelard A; Department of Pathology, Bichat Hospital, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Source: British journal of cancer [Br J Cancer] 2025 Aug; Vol. 133 (3), pp. 420.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE; PubMed not MEDLINE

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Authors: Sorbye H; Cancer Clinic, Haukeland University Hospital, Bergen, Norway. halfdan.sorbye@helse-bergen.no.; Department of Clinical Science, University of Bergen, Bergen, Norway. halfdan.sorbye@helse-bergen.no., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Sundlöv A; Department of Oncology, Skåne University Hospital, Lund, Sweden., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Hofsli E; Department of Oncology, St.Olavs Hospital, Trondheim, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Morken S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Tabaksblat E; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Couvelard A; Department of Pathology, Bichat Hospital, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Source: British journal of cancer [Br J Cancer] 2025 Aug; Vol. 133 (3), pp. 316-324. Date of Electronic Publication: 2025 May 17.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

MeSH Terms: Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/drug therapy , Neuroendocrine Tumors*/mortality , Digestive System Neoplasms*/pathology , Digestive System Neoplasms*/drug therapy , Digestive System Neoplasms*/mortality, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Male ; Female ; Middle Aged ; Aged ; Prospective Studies ; Adult ; Prognosis ; Aged, 80 and over ; Treatment Outcome ; Neoplasm Grading

Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials.

Authors: Gamrath L; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Pedersen TB; Department of Clinical Diagnostics, University Hospital of Southern Denmark, Esbjerg, Denmark., Møller MV; Department of Clinical Diagnostics, University Hospital of Southern Denmark, Esbjerg, Denmark., Volmer LM; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark.; Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark., Holst-Christensen L; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Donskov F; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark. fdonskov@health.sdu.dk.; Department of Regional Health Science, University of Southern Denmark, Odense, Denmark. fdonskov@health.sdu.dk.

Source: Current oncology reports [Curr Oncol Rep] 2025 Jan; Vol. 27 (1), pp. 45-58. Date of Electronic Publication: 2025 Jan 03.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE

MeSH Terms: Neoplasms*/drug therapy , Immune Checkpoint Inhibitors*/therapeutic use , Immunotherapy* , Gastrointestinal Microbiome*, Bacteria/classification ; Clinical Trials as Topic ; Humans ; Diet ; Metabolome

NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms.

Authors: Sorbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Danish Medicines Agency, Copenhagen, Denmark., Sundlov A; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Couvelard A; Department of Pathology, AP-HP Bichat Hospital, Université Paris Cité, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Langer SW; Department of Oncology, Copenhagen University Hospital - Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Source: Journal of neuroendocrinology [J Neuroendocrinol] 2024 Nov; Vol. 36 (11), pp. e13428. Date of Electronic Publication: 2024 Jun 27.

Publication Type: Journal Article; Observational Study

Journal Info: Publisher: Wiley & Sons Country of Publication: United States NLM ID: 8913461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2826 (Electronic) Linking ISSN: 09538194 NLM ISO Abbreviation: J Neuroendocrinol Subsets: MEDLINE

MeSH Terms: Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/drug therapy , Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/diagnosis , Intestinal Neoplasms*/pathology , Intestinal Neoplasms*/drug therapy , Intestinal Neoplasms*/mortality , Intestinal Neoplasms*/diagnosis , Stomach Neoplasms*/pathology , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/diagnosis, Biomarkers, Tumor/blood ; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Neoplasm Grading ; Prospective Studies

SCR Disease Name: Gastro-enteropancreatic neuroendocrine tumor

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.

Authors: Elvebakken H; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. Hege.Elvebakken@helse-mr.no.; Department of Oncology, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway. Hege.Elvebakken@helse-mr.no., Venizelos A; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Couvelard A; Department of Pathology, Université Paris Cité and AP-HP, Bichat Hospital, Paris, France., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Myklebust TÅ; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.; Department of Registration, Cancer Registry Norway, Oslo, Norway., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Hofsli E; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Oncology, St.Olavs Hospital, Trondheim, Norway., Detlefsen S; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., Vestermark LW; Danish Medicines Agency, Copenhagen, Denmark., Knappskog S; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.

Source: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (4), pp. 676-684. Date of Electronic Publication: 2024 Jun 22.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

MeSH Terms: Neuroendocrine Tumors*/genetics , Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/drug therapy , Mutation*, Etoposide/administration & dosage ; Carcinoma, Neuroendocrine/genetics ; Carcinoma, Neuroendocrine/pathology ; Carcinoma, Neuroendocrine/drug therapy ; Carboplatin/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Tumor Suppressor Protein p53/genetics ; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Treatment Outcome ; Prognosis ; Aged, 80 and over ; DNA Copy Number Variations ; Prospective Studies ; Neoplasm Grading ; Young Adult

Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.

Authors: Morken S; Department of Oncology, Haukeland University Hospital, Bergen, Norway. siren.morken@helse-bergen.no., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Sundlöv A; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Svensson JB; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Tabaksblat EM; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Haslerud TM; Department of Radiology and Nuclear Medicine, Haukeland University Hospital, Bergen, Norway., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Detlefsen S; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., Couvelard A; Department of Pathology, Bichat Hospital, Paris, France., Perren A; Institute of Tissue medicine and Pathology, University of Bern, Bern, Switzerland., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.

Source: British journal of cancer [Br J Cancer] 2023 Dec; Vol. 129 (12), pp. 1930-1939. Date of Electronic Publication: 2023 Oct 23.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

MeSH Terms: Neuroendocrine Tumors*/pathology , Pancreatic Neoplasms*/pathology, Everolimus/adverse effects ; Humans ; Temozolomide ; Quality of Life ; Prospective Studies

Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.

Authors: Venizelos A; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway.; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Couvelard A; Department of Pathology, Université Paris Cité and AP-HP, Bichat Hospital, Paris, France., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Sundlöv A; Departmentt of Oncology, Skåne University Hospital, Lund, Sweden.; Department of Medical Radiation Physics, Lund University, Lund, Sweden., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Hofsli E; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Oncology, St. Olavs Hospital, Trondheim, Norway., Detlefsen S; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Tabaksblat EM; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Knappskog S; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.

Source: Endocrine-related cancer [Endocr Relat Cancer] 2023 Aug 23; Vol. 30 (10). Date of Electronic Publication: 2023 Aug 23 (Print Publication: 2023).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BioScientifica Country of Publication: England NLM ID: 9436481 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1479-6821 (Electronic) Linking ISSN: 13510088 NLM ISO Abbreviation: Endocr Relat Cancer Subsets: MEDLINE

MeSH Terms: Pancreatic Neoplasms*/genetics , Pancreatic Neoplasms*/pathology , Gastrointestinal Neoplasms*/genetics , Neuroendocrine Tumors*/pathology , Carcinoma, Neuroendocrine*/pathology , Intestinal Neoplasms*/genetics , Intestinal Neoplasms*/pathology , Stomach Neoplasms*/genetics , Stomach Neoplasms*/pathology, Humans ; Germ-Line Mutation

Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.

Authors: Pommergaard HC; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Nielsen K; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Federspiel B; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Tabaksblat EM; ENETS Neuroendocrine Tumor Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Janson ET; ENETS Neuroendocrine Tumor Centre of Excellence, Uppsala University Hospital, Uppsala, Sweden.; Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden., Hansen CP; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Ladekarl M; ENETS Neuroendocrine Tumor Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Hjortland GO; ENETS Neuroendocrine Tumor Centre of Excellence, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Sundlöv A; Department of Oncology, Skåne University Hospital, Lund, Sweden., Galleberg R; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Knigge P; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, University of Copenhagen and Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Kjaer A; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, University of Copenhagen and Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Langer SW; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Knigge U; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Source: Journal of neuroendocrinology [J Neuroendocrinol] 2021 May; Vol. 33 (5), pp. e12967. Date of Electronic Publication: 2021 Mar 26.

Publication Type: Journal Article

Journal Info: Publisher: Wiley & Sons Country of Publication: United States NLM ID: 8913461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2826 (Electronic) Linking ISSN: 09538194 NLM ISO Abbreviation: J Neuroendocrinol Subsets: MEDLINE

MeSH Terms: Intestinal Neoplasms/*surgery , Neuroendocrine Tumors/*surgery , Pancreatic Neoplasms/*surgery , Stomach Neoplasms/*surgery, Intestinal Neoplasms/mortality ; Intestinal Neoplasms/pathology ; Neuroendocrine Tumors/mortality ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Survival Rate ; Treatment Outcome

SCR Disease Name: Gastro-enteropancreatic neuroendocrine tumor

A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.

Authors: Elvebakken H; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway, hege.elvebakken@helse-mr.no.; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway, hege.elvebakken@helse-mr.no., Perren A; Institute of Pathology, University of Bern, Bern, Switzerland., Scoazec JY; Department of Biopathology, Institut Gustave Roussy, Villejuif, France., Tang LH; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Federspiel B; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Klimstra DS; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Zlobec I; Institute of Pathology, University of Bern, Bern, Switzerland., Myklebust TÅ; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.; Department of Registration, Cancer Registry Norway, Oslo, Norway., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Langer SW; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Gronbaek H; Department of Hepatology & Gastroenterology, Aarhus University Hospital & ENETS Center of Excellence, Aarhus, Denmark., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Tiensuu Janson E; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.

Source: Neuroendocrinology [Neuroendocrinology] 2021; Vol. 111 (9), pp. 883-894. Date of Electronic Publication: 2020 Oct 01.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0035665 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0194 (Electronic) Linking ISSN: 00283835 NLM ISO Abbreviation: Neuroendocrinology Subsets: MEDLINE

MeSH Terms: Intestinal Neoplasms*/diagnosis , Intestinal Neoplasms*/mortality , Intestinal Neoplasms*/pathology , Neuroendocrine Tumors*/diagnosis , Neuroendocrine Tumors*/mortality , Neuroendocrine Tumors*/pathology , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/mortality , Pancreatic Neoplasms*/pathology , Stomach Neoplasms*/diagnosis , Stomach Neoplasms*/mortality , Stomach Neoplasms*/pathology , Registries*, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Consensus ; Neoplasm Grading ; Progression-Free Survival ; Practice Guidelines as Topic

SCR Disease Name: Gastro-enteropancreatic neuroendocrine tumor

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Authors: Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. abir.ali@medsci.uu.se., Grönberg M; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Langer SW; Departments of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Österlund P; Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland.; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Welin S; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Grønbæk H; Departments of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Knigge U; Departments of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.

Source: Medical oncology (Northwood, London, England) [Med Oncol] 2018 Mar 06; Vol. 35 (4), pp. 47. Date of Electronic Publication: 2018 Mar 06.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

MeSH Terms: Antineoplastic Agents, Phytogenic/*administration & dosage , Etoposide/*administration & dosage , Intestinal Neoplasms/*drug therapy , Neuroendocrine Tumors/*drug therapy , Pancreatic Neoplasms/*drug therapy , Stomach Neoplasms/*drug therapy, Antineoplastic Agents, Phytogenic/adverse effects ; Etoposide/adverse effects ; Intestinal Neoplasms/mortality ; Neuroendocrine Tumors/mortality ; Pancreatic Neoplasms/mortality ; Stomach Neoplasms/mortality ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Infusions, Intravenous ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome

SCR Disease Name: Gastro-enteropancreatic neuroendocrine tumor

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Authors: Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Grönberg M; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Federspiel B; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Scoazec JY; Department of Biopathology, Institut Gustave Roussy, Villejuif, France., Hjortland GO; Department of Oncology, Oslo University, Oslo, Norway., Grønbæk H; Department of Hepatology & Gastroenterology, Aarhus university Hospital, Aarhus, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Langer SW; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Welin S; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Arola J; Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Österlund P; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland.; Department of Oncology, Tampere University Hospital, Tampere, Finland., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Sorbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway., Grimelius L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.

Source: PloS one [PLoS One] 2017 Nov 07; Vol. 12 (11), pp. e0187667. Date of Electronic Publication: 2017 Nov 07 (Print Publication: 2017).

Publication Type: Journal Article

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

MeSH Terms: Carcinoma, Neuroendocrine/*metabolism , Gastrointestinal Neoplasms/*metabolism , Pancreatic Neoplasms/*metabolism , Tumor Suppressor Protein p53/*metabolism, Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/pathology ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Neoplasms/pathology ; Ki-67 Antigen/metabolism ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Aged ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

Authors: Galleberg RB; Department of Oncology, Haukeland University Hospital, Bergen, Norway. Electronic address: renate.berget.galleberg@helse-bergen.no., Knigge U; Departments of Surgery C and Endocrinology PE, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: rxs484@ku.dk., Tiensuu Janson E; Department of Medical Sciences, Uppsala University, Sweden. Electronic address: eva.tiensuu_janson@medsci.uu.se., Vestermark LW; Department of Oncology, Odense University Hospital, Denmark. Electronic address: lene.vestermark@syd.dk., Haugvik SP; Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Norway. Electronic address: sphaugvik@yahoo.de., Ladekarl M; Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: mortlade@rm.dk., Langer SW; Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: swlanger@dadlnet.dk., Grønbæk H; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark. Electronic address: henning.gronbaek@aarhus.rm.dk., Österlund P; Department of Oncology, Helsinki University Central Hospital, Finland. Electronic address: pia.osterlund@pshp.fi., Hjortland GO; Department of Oncology, Oslo University Hospital, Norway. Electronic address: goo@ous-hf.no., Assmus J; Center for Clinical Research, Haukeland University Hospital, Bergen, Norway. Electronic address: jorg.assmus@helse-bergen.no., Tang L; Department of Pathology, MSKCC, New York, USA. Electronic address: tangl@MSKCC.ORG., Perren A; Department of Pathology, University of Bern, Switzerland. Electronic address: aurel.perren@pathology.unibe.ch., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Norway. Electronic address: Halfdan.sorbye@helse-bergen.no.

Source: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2017 Sep; Vol. 43 (9), pp. 1682-1689. Date of Electronic Publication: 2017 May 04.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 8504356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2157 (Electronic) Linking ISSN: 07487983 NLM ISO Abbreviation: Eur J Surg Oncol Subsets: MEDLINE

MeSH Terms: Carcinoma, Neuroendocrine/*surgery , Intestinal Neoplasms/*pathology , Liver Neoplasms/*surgery , Pancreatic Neoplasms/*pathology , Stomach Neoplasms/*pathology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/pathology ; Carcinoma, Neuroendocrine/secondary ; Catheter Ablation/adverse effects ; Hepatectomy/adverse effects ; Ki-67 Antigen/analysis ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary ; Adult ; Aged ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Recurrence ; Survival Rate

S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies.

Authors: Pfeiffer P; a Department of Oncology , Odense University Hospital , Odense , Denmark.; b Institute of Clinical Research, University of Southern Denmark , Odense , Denmark., Qvortrup C; a Department of Oncology , Odense University Hospital , Odense , Denmark., Krogh M; a Department of Oncology , Odense University Hospital , Odense , Denmark., Schoennemann K; a Department of Oncology , Odense University Hospital , Odense , Denmark., Vestermark LW; a Department of Oncology , Odense University Hospital , Odense , Denmark., Jensen HA; a Department of Oncology , Odense University Hospital , Odense , Denmark., Bjerregaard JK; a Department of Oncology , Odense University Hospital , Odense , Denmark.

Source: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2017 Jan; Vol. 56 (1), pp. 46-51. Date of Electronic Publication: 2016 Dec 02.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

MeSH Terms: Adenocarcinoma/*drug therapy , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Esophageal Neoplasms/*drug therapy , Stomach Neoplasms/*drug therapy, Adenocarcinoma/pathology ; Esophageal Neoplasms/pathology ; Organoplatinum Compounds/administration & dosage ; Oxonic Acid/administration & dosage ; Stomach Neoplasms/pathology ; Taxoids/administration & dosage ; Tegafur/administration & dosage ; Aged ; Docetaxel ; Drug Combinations ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin ; Prognosis ; Survival Rate

Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.

Authors: Winther SB; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Zubcevic K; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Qvortrup C; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Vestermark LW; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Jensen HA; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Krogh M; a Department of Oncology , Odense University Hospital , Odense , Denmark ;, Sorbye H; b Department of Oncology , Haukeland University Hospital , Bergen , Norway., Pfeiffer P; a Department of Oncology , Odense University Hospital , Odense , Denmark ;

Corporate Authors: Academy of Geriatric Cancer Research (AgeCare)

Source: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2016 Jul; Vol. 55 (7), pp. 881-5. Date of Electronic Publication: 2016 May 16.

Publication Type: Clinical Trial; Journal Article; Multicenter Study

Journal Info: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Colorectal Neoplasms/*drug therapy , Colorectal Neoplasms/*pathology , Oxonic Acid/*therapeutic use , Tegafur/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/mortality ; Diarrhea/chemically induced ; Fatigue/chemically induced ; Organoplatinum Compounds/administration & dosage ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Aged ; Aged, 80 and over ; Drug Combinations ; Female ; Humans ; Irinotecan ; Male ; Oxaliplatin ; Treatment Outcome